Home › Intervertebral Disc Degeneration › NCT05329129

OssDsign® Spine Registry Study ("Propel")

PROSPECTIVE OBSERVATIONAL SPINE FUSION REGISTRY FOR OssDsign® BONE GRAFT SUBSTITUTES IN REAL WORLD CLINICAL PRACTICE

Who can join

Ages 21 and older · All sexes

* The patient has been diagnosed as a candidate for spinal fusion surgery for which the surgeon has decided an OssDsign® bone graft is appropriate.
* The patient is ≥21 years old.
* The patient is, in the investigator's opinion, psychosocially, mentally, and physically able to fully comply with this protocol, including the post-operative regimen, required follow-up visits, the filling out of required forms, and have the ability to understand and give written informed consent
* The patient is willing and able to participate in post- operative clinical and radiographic follow up evaluations for 2 years.

Exclusion Criteria:

* Patients not meeting all of the inclusion criteria

About the study

The purpose of this multi-center, prospective, observational registry is to gather information on the clinical outcomes and real-world use of commercially available bone graft substitutes manufactured by OssDsign® AB, in patients who require spine fusion.

What is being tested

• OssDsign® Catalyst (device)

Sponsor: OssDsign · Participants: 450 · Started: Mar 23, 2022

Contact the study team

• jeff Feldhaus · Phone: 13476694903
• Pete weiman · Phone: 13479540542

Official record on ClinicalTrials.gov — NCT05329129

Locations in the U.S.

Conditions

• Intervertebral Disc Degeneration
• Spinal Stenosis

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.